PMID- 37071391
OWN - NLM
STAT- MEDLINE
DCOM- 20230724
LR  - 20230724
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 83
IP  - 2
DP  - 2023 Aug
TI  - PD-L1 and HLA-class I expression status and their therapeutic implication in 
      oesophageal small-cell carcinoma.
PG  - 264-275
LID - 10.1111/his.14924 [doi]
AB  - AIMS: Oesophageal small-cell carcinoma is a rare and highly aggressive subtype of 
      oesophageal cancer with a dismal prognosis. To explore the potential 
      applicability of immunotherapy, we investigated the expression status of 
      programmed death ligand 1 (PD-L1) and human leukocyte antigen (HLA)-class I and 
      the degree of tumour-infiltrating lymphocytes (TILs) in oesophageal small-cell 
      carcinoma. METHODS AND RESULTS: PD-L1 and HLA-class I expression levels were 
      evaluated in 10 pure small-cell carcinomas and five mixed 
      neuroendocrine-non-neuroendocrine neoplasms (MiNENs). The combined positive score 
      (CPS) and tumour proportion score (TPS) were used for PD-L1 assessment. 
      Immunohistochemistry for mismatch repair (MMR) proteins was also performed. PD-L1 
      immunohistochemistry demonstrated CPS >/=1 in nine (60%), CPS >/=10 in five (33%), 
      and TPS >/=1 in five (33%) cases. Overall survival was significantly longer in 
      patients with CPS >/=1 than in those with CPS <1. HLA-class I deficiency (>50% 
      tumour cells) was noted in five cases (33%), with no significant correlation with 
      PD-L1 expression status. Among the five MiNENs, HLA-class I expression was 
      decreased in the small-cell carcinoma component of three cases. HLA-class I 
      deficiency was significantly associated with higher TNM stage and reduced TIL 
      levels. MMR deficiency was not observed in any case. CONCLUSION: Given that a 
      significant subset (40%) exhibited PD-L1 CPS >/=1 with preserved HLA-class I 
      expression and high levels of TIL, the PD-1/PD-L1 pathway is a potential 
      therapeutic target for oesophageal small-cell carcinoma.
CI  - (c) 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.
FAU - Yamashita, Satoshi
AU  - Yamashita S
AD  - Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, 
      Japan.
AD  - Department of Gastrointestinal Surgery, Graduate School of Medicine, University 
      of Tokyo, Tokyo, Japan.
FAU - Abe, Hiroyuki
AU  - Abe H
AUID- ORCID: 0000-0003-4513-1007
AD  - Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, 
      Japan.
FAU - Yamashita, Hiroharu
AU  - Yamashita H
AD  - Department of Gastrointestinal Surgery, Graduate School of Medicine, University 
      of Tokyo, Tokyo, Japan.
AD  - Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, 
      Japan.
FAU - Yagi, Koichi
AU  - Yagi K
AD  - Department of Gastrointestinal Surgery, Graduate School of Medicine, University 
      of Tokyo, Tokyo, Japan.
FAU - Seto, Yasuyuki
AU  - Seto Y
AD  - Department of Gastrointestinal Surgery, Graduate School of Medicine, University 
      of Tokyo, Tokyo, Japan.
FAU - Ushiku, Tetsuo
AU  - Ushiku T
AD  - Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, 
      Japan.
LA  - eng
GR  - Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20230418
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Humans
MH  - *B7-H1 Antigen/metabolism
MH  - Biomarkers, Tumor/metabolism
MH  - *Esophageal Neoplasms/pathology
MH  - *Histocompatibility Antigens Class I/metabolism
MH  - Lymphocytes, Tumor-Infiltrating/pathology
MH  - Prognosis
OTO - NOTNLM
OT  - HLA-class I
OT  - combined positive score
OT  - molecular targeted therapy
OT  - oesophageal small-cell carcinoma
OT  - programmed death ligand 1
EDAT- 2023/04/19 06:00
MHDA- 2023/07/10 06:42
CRDT- 2023/04/18 11:29
PHST- 2023/03/14 00:00 [revised]
PHST- 2023/01/12 00:00 [received]
PHST- 2023/04/01 00:00 [accepted]
PHST- 2023/07/10 06:42 [medline]
PHST- 2023/04/19 06:00 [pubmed]
PHST- 2023/04/18 11:29 [entrez]
AID - 10.1111/his.14924 [doi]
PST - ppublish
SO  - Histopathology. 2023 Aug;83(2):264-275. doi: 10.1111/his.14924. Epub 2023 Apr 18.